Document is current
Any future updates will be listed below
-
Authors
Chen, Shimin
Hu, Shangying
Yin, Jian
Yu, Wenying
Zhang, Xun
Deng, Xi
Ding, Huaxin
Zhang, Jinyu
Song, Yan
Wang, Qiming
Chen, Liang
Guo, Feng
Hartwig, Susanne
Zhao, Fanghui
-
Funding
Funding for this research was provided by:
Merck (NIS009237)
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 16 July 2024
First Online: 12 September 2024
Declarations
:
: This study was approved by the Institutional Review Boards (IRBs)/Ethics Review Committees (ERCs) of the Cancer Hospital, Chinese Academy of Medical Sciences (CHCAMS) (Approval No. 20/376-2572). Since only archived specimens and information were used, a waiver for informed consent was approved by the IRBs/ERCs of the CHCAMS for all included patients.
: Fanghui Zhao received grants from GlaxoSmithKline Biologicals, Merck & Co., and Xiamen Innovax Biotech to the Cancer Hospital/Chinese Academy of Medical Sciences to undertake clinical trials on the human papillomavirus (HPV) vaccine. Feng Guo and Susanne Hartwig are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Susanne Hartwig owns stock in Merck & Co., Inc., Rahway, NJ, USA. The other coauthors declare no competing interests.
: No datasets were generated or analysed during the current study.
